Logo

Logo

Lancet

Coronavirus vax. cuts risk of long Covid: Lancet

The study, led by King's College London, found that of more than 1.2 million adults who received at least one dose of either the Pfizer-BioNTech, Oxford-AstraZeneca, or Moderna vaccine, between December 2020 and July 2021, fewer than 0.5 per cent reported a breakthrough infection more than 14 days after their first dose.

Darkness at noon

All stakeholders ~ governments at the Centre and states, health professionals, urban planners, environmentalists and most importantly the citizens, who bear the brunt of this health hazard as they go about their daily routine ~ must be consulted before chalking out an action plan to deal with this dire scenario.